Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-21

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Menu

    895519-91-2 (mesylate)

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 895519-91-2, Flumatinib (mesylate), 95y8l63nbc, N-(6-methyl-5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)pyridin-3-yl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide methanesulfonate, 895519-91-2 (mesylate), Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-n-[6-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-3-pyridinyl]-3-(trifluoromethyl)-, monomethanesulfonate (9ci)
    Molecular Formula
    C30H33F3N8O4S
    Molecular Weight
    658.7  g/mol
    InChI Key
    ZSASDYCFROUKTJ-UHFFFAOYSA-N
    FDA UNII
    95Y8L63NBC
    Flumatinib Mesylate is the orally bioavailable, mesylate salt form of the tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity. Upon administration, flumatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed. Bcr-Abl fusion protein is an abnormal, constitutively active enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. c-kit, a receptor tyrosine kinase mutated and constitutively activated in certain tumors, plays a key role in tumor cell survival, proliferation, and differentiation.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[6-methyl-5-[(4-pyridin-3-ylpyrimidin-2-yl)amino]pyridin-3-yl]-3-(trifluoromethyl)benzamide
    2.1.2 InChI
    InChI=1S/C29H29F3N8O.CH4O3S/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40;1-5(2,3)4/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38);1H3,(H,2,3,4)
    2.1.3 InChI Key
    ZSASDYCFROUKTJ-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=C(C=C(C=N1)NC(=O)C2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    95Y8L63NBC
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. 895519-91-2

    2. Flumatinib (mesylate)

    3. 95y8l63nbc

    4. N-(6-methyl-5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)pyridin-3-yl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide Methanesulfonate

    5. 895519-91-2 (mesylate)

    6. Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-n-[6-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-3-pyridinyl]-3-(trifluoromethyl)-, Monomethanesulfonate (9ci)

    7. Hhgv678 Mesylate

    8. N-(6-methyl-5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)pyridin-3-yl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide Mesylate

    9. Unii-95y8l63nbc

    10. Hh-gv-678 Mesylate

    11. Schembl4889246

    12. Chembl3901539

    13. Dtxsid70237780

    14. Bcp08647

    15. Ex-a2059

    16. Vkb51991

    17. Flumatinib Mesylate [who-dd]

    18. Mfcd28053502

    19. Cs-1826

    20. Da-33624

    21. Hy-13905

    22. Methanesulfonic Acid;4-[(4-methylpiperazin-1-yl)methyl]-n-[6-methyl-5-[(4-pyridin-3-ylpyrimidin-2-yl)amino]pyridin-3-yl]-3-(trifluoromethyl)benzamide

    23. Ft-0752643

    24. E73439

    25. Q27271825

    26. Benzamide, 4-((4-methyl-1-piperazinyl)methyl)-n-(6-methyl-5-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-3-pyridinyl)-3-(trifluoromethyl)-, Methanesulfonate (1:1)

    27. Benzamide, 4-((4-methyl-1-piperazinyl)methyl)-n-(6-methyl-5-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-3-pyridinyl)-3-(trifluoromethyl)-, Monomethanesulfonate

    2.4 Create Date
    2010-10-11
    3 Chemical and Physical Properties
    Molecular Weight 658.7 g/mol
    Molecular Formula C30H33F3N8O4S
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count14
    Rotatable Bond Count7
    Exact Mass658.22975722 g/mol
    Monoisotopic Mass658.22975722 g/mol
    Topological Polar Surface Area162 Ų
    Heavy Atom Count46
    Formal Charge0
    Complexity934
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2